Answers are grounded in this paper and cite their sources.
Epsilon-lysine branched (ε-Kb) glucagon-like peptide-1 (GLP-1) analogs comprise a prominent class of peptide therapeutics, altering the outlook for illnesses such as type 2 diabetes and obesity, in turn necessitating manufacturing on up to ton scales. Nevertheless, the lack of sustainable approaches to ε-Kb GLP-1s has raised concerns about the viability of making ε-Kb GLP-1s with current manufacturing methods. We report a solid-phase peptide synthesis (SPPS) approach to ε-Kb GLP-1s demonstrated by a four-α-disubstituted unnatural amino acid (uAA) containing GLP-1 triple agonist as a substrate. Our approach to ε-Kb GLP-1s encompassed efficient DMF-free SPPS, which required addressing solvent quality issues and metal-free Lys(Alloc) removal, for which a His iodination side reaction had to be tackled. Minimizing the footprint of the synthesis was achieved by a dual strategy, eliminating postcoupling washes and recycling the SPPS waste stream, while FeCl 3 /AcOH cleavage of ε-Kb GLP-1 peptide resin marks the expansion of TFA-free resin cleavage from 10AA to ∼40AA peptides. Taken together, our approach constitutes the first truly sustainable SPPS route to ε-Kb GLP-1s, opening up a new frontier in the commercially viable and environmentally responsible manufacturing of this notable class of incretin peptide drugs.
No takes yet. Share an insight, caveat, or question.
Pawlas et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: